Yuji Yamaguchi
Overview
Explore the profile of Yuji Yamaguchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
1884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peeva E, Guttman-Yassky E, Yamaguchi Y, Berman B, Oemar B, Ramakrishna J, et al.
Drug Discov Today
. 2025 Feb;
30(3):104317.
PMID: 39986647
Evolving research landscapes warrant updates in drug development strategy. Collaborations between pharmaceutical industry and academic institutions are crucial for accelerating drug development, leveraging individual expertise in clinical trial conduct and...
2.
Sato K, Hiraga Y, Yamaguchi Y, Sakaki S, Takenaka H
Life (Basel)
. 2025 Jan;
14(12.
PMID: 39768251
This study investigated the multifaceted benefits of water extract across various cell lines, including murine B16F1 melanoma cells, human keratinocyte HaCaT cells, and human follicle dermal papilla cells (HFDPCs), to...
3.
Yamaguchi Y, Peeva E, Adiri R, Ghosh P, Napatalung L, Hamzavi I, et al.
J Am Acad Dermatol
. 2024 Dec;
PMID: 39709084
Background: Ritlecitinib demonstrated efficacy in a phase 2b trial of nonsegmental vitiligo. Objective: To evaluate the efficacy and tolerability of ritlecitinib with add-on narrow-band ultraviolet B (nbUVB) phototherapy in patients...
4.
Peeva E, Yamaguchi Y, Ye Z, King B, Picardo M, Sloan A, et al.
Exp Dermatol
. 2024 Sep;
33(9):e15177.
PMID: 39304339
Efficacy and safety of ritlecitinib (an oral JAK3/TEC family kinase inhibitor) were evaluated in patients with nonsegmental vitiligo (NSV) across Fitzpatrick skin types (FSTs). Patients with FST I-III ('light skin';...
5.
Yamaguchi H, Yamaguchi Y, Peeva E
J Eur Acad Dermatol Venereol
. 2024 Sep;
39(3):498-511.
PMID: 39258892
Both alopecia areata (AA) and vitiligo share common pathogenesis involving, interferon-γ (IFN-γ) and interleukin-15 (IL-15) signalling pathways that activate cytotoxic CD8+ T lymphocytes. These shared mechanisms may explain why both...
6.
Yamaguchi Y, Peeva E, Del Duca E, Facheris P, Bar J, Shore R, et al.
Arch Dermatol Res
. 2024 Jul;
316(7):478.
PMID: 39023568
The efficacy of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, on active and stable lesions was evaluated in patients with active non-segmental vitiligo in a phase 2b trial (NCT03715829). Patients...
7.
Yamaguchi H, Yamaguchi Y, Peeva E
Int J Mol Sci
. 2024 Apr;
25(8).
PMID: 38673994
Both alopecia areata (AA) and vitiligo are distinct, heterogenous, and complex disease entities, characterized by nonscarring scalp terminal hair loss and skin pigment loss, respectively. In AA, inflammatory cell infiltrates...
8.
Oka Y, Hamano Y, Nakamura R, Mabuchi K, Ochi M, Yamaguchi Y, et al.
Nihon Shokakibyo Gakkai Zasshi
. 2024 Mar;
121(3):221-229.
PMID: 38462470
With the advent of immune checkpoint inhibitors (ICI), cancer treatment options have widened in recent years. However, ICI-specific adverse events (irAEs) have been reported. Lower gastrointestinal lesions, such as colitis...
9.
Olopoenia A, Yamaguchi Y, Peeva E, Berman B, Jagun O, George P
Int J Dermatol
. 2024 Feb;
63(8):e163-e170.
PMID: 38411301
Introduction: There is limited epidemiologic evidence on keloids using real-world data, especially in the United States (US) across race and ethnicity. Methods: We conducted a retrospective cohort study using Cerner...
10.
Yamaguchi Y, Okajima F, Sugihara H, Iwabu M, Emoto N
J Nippon Med Sch
. 2023 Dec;
91(1):48-58.
PMID: 38072422
Background: This study examined the appropriateness of the current paradigm for differential diagnosis of painless thyroiditis and Graves' disease (GD) in patients with thyrotoxicosis. Methods: We retrospectively evaluated the clinical...